Computational approaches elucidate TLR interactions with AMPs, suggesting new pathways for immune response against candida.
Despite the considerable pathogenic impact of Candida albicans in human health, the gap in understanding the cellular recognition mechanisms and subsequent host defence activation remain insufficiently understood. Recent insights underscore the pivotal role of Toll-like receptors (TLRs) in organising innate immune responses against pathogens. Notably, empirical investigations over recent years have underscored TLRs as paramount pattern-recognition receptors in mammals. TLR2, for examples, exhibits affinity for peptidoglycans, lipoarabinomannan, and bacterial lipoproteins, while TLR4 implicated in detecting lipopolysaccharide (LPS) and lipo-teichoic acid. Similarly, TLR5 recognizes flagellin, and TLR9 is associated with bacterial DNA recognition. The initial identification of Toll in Drosophila as a regulator of antifungal mechanisms suggests the potential involvement of TLRs in mammalian antifungal defence. However, scant attention has been devoted to delineating the role of TLRs in combating fungal pathogens in humans, despite the evolutionary link between Toll in Drosophila and antifungal mechanisms, suggesting a plausible involvement of TLRs in mammalian antifungal defense. Notably, evidence implicates TLR4, but not TLR2, in inducing proinflammatory cytokines in response to Aspergillus fumigatus, while its role is purported to mediate intracellular signaling, albeit not TNF production, after stimulation of cells with Cryptococcus neoformans. However, insights into TLR activation rules have enabled the examination of antimicrobial peptide (AMP) interactions with TLRs, facilitating predictions regarding the immunomodulatory capacities of diverse molecules. Despite these advancements, the specific role of TLRs in recognizing Candida albicans, a prominent human pathogen, remains elusive, warranting further investigation. This computational approach synthesizes recent findings elucidating the interactions between AMPs and TLRs, delineating the structural determinants governing TLR activation, thus enabling predictive insights into the immunomodulatory potential of diverse molecular entities
No takes yet. Share an insight, caveat, or question.
Biçer et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: